Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.71 |
| ▸ | CNR1 | P21554 | 7/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 2/20 | 0.48 |
| ▸ | LGMN | Q99538 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1464096 | 0.84 | CNR2 (0.67) | CNR2CNR1GAACYP2D6CYP2C19 | |
| SCHEMBL1463732 | 0.83 | CNR2 (1.00) | CNR2CNR1GAACYP2D6CYP2C19 | |
| SCHEMBL1465613 | 0.79 | CNR2 (0.66) | CNR2CNR1GAACYP2D6CYP2C19 | |
| SCHEMBL1464021 | 0.77 | CNR2 (0.64) | CNR2CNR1GAACYP2D6CYP2C19 | |
| SCHEMBL1463871 | 0.76 | CNR2 (0.65) | CNR2CNR1GAACYP2D6CYP2C19 | |
| SCHEMBL2259456 | 0.75 | MAPK14 (0.56) | CNR2CNR1GAAAREGFR | |
| SCHEMBL1464776 | 0.75 | CNR2 (0.84) | CNR2CNR1GAAEGFRFLT3 | |
| SCHEMBL1463652 | 0.74 | CNR2 (0.62) | CNR2CNR1GAACYP2D6CYP2C19 | |
| SCHEMBL12095707 | 0.74 | CNR2 (0.62) | CNR2CNR1GAACYP2D6CYP2C19 | |
| SCHEMBL1463528 | 0.74 | CNR2 (0.78) | CNR2CNR1GAACYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595959-B1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2015-11-04 | — | — | EP | disclosed |
| US-8846936-B2 | Sulfonyl compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-8846936-B2 | Sulfonyl compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-20130184315-A1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130184315-A1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| WO-2012012307-A9 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012012307-A1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184315-A1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | CNR2, CNR1, GPR52 | CNR2 1/4885CNR1 2/4885GAA 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.